Dillon & Associates Inc Regeneron Pharmaceuticals, Inc. Transaction History
Dillon & Associates Inc
- $721 Million
- Q4 2024
A detailed history of Dillon & Associates Inc transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Dillon & Associates Inc holds 13,899 shares of REGN stock, worth $9.73 Million. This represents 1.37% of its overall portfolio holdings.
Number of Shares
13,899
Previous 13,525
2.77%
Holding current value
$9.73 Million
Previous $14.2 Million
30.38%
% of portfolio
1.37%
Previous 2.0%
Shares
17 transactions
Others Institutions Holding REGN
# of Institutions
1,487Shares Held
85.7MCall Options Held
1.53MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.5 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.92 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$4.94 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.83MShares$3.38 Billion0.14% of portfolio
-
Capital International Investors Los Angeles, CA4.74MShares$3.32 Billion0.66% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $75.1B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...